Original Article MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer

Zhenfeng Hao¹, Jishi Yang¹, Chenghai Wang², Yaoyao Li³, Yu Zhang³, Xiaoyun Dong³, Liulin Zhou¹, Jing Liu¹, Yanqing Zhang², Jing Qian³

¹Department of Obstetrics and Gynecology, Taixing People's Hospital Affiliated to Yangzhou University, Taizhou 225004, Jiangshu, China; ²Department of Pathology, Medical College of Yangzhou University, Yangzhou 225001, Jiangshu, China; ³Jiangsu Key Laboratory of Intergrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou University, Yangzhou 225001, Jiangshu, China

Received October 26, 2014; Accepted January 7, 2015; Epub January 15, 2015; Published January 30, 2015

Abstract: MicroRNAs (miRNAs) are aberrantly expressed in cervical cancer. miR-7 has been demonstrated to function as both an oncogene and a tumor suppressor in some types of human cancers. In the present study, miR-7 was significantly downregulated in cervical cancer, especially metastatic tumors. Ectopic expression of miR-7 significantly inhibited metastasis and invasion in Hela and C33A cells. Upregulated miR-7 significantly suppressed focal adhesion kinase (FAK) at transcriptional and translational levels. Furthermore, the level of FAK was negatively correlated with miR-7 in cervical cancer tissues. In conclusion, miR-7 inhibited the metastasis and invasion of cervical cancer at least partially through targeting FAK. The findings of this study provide novel insight with potential therapeutic applications for the treatment of metastatic cervical cancer.

Keywords: microRNA, miR-7, focal adhesion kinase, cervical cancer, metastasis, invasion

Introduction

MicroRNAs (miRNAs) are endogenous, small (18~25 nucleotides) non-coding RNA that typically suppress gene expression by binding to 3' untranslated regions (UTRs) of their target mRNAs for degradation [1, 2]. More than 60% of human protein-coding genes has been under selective pressure to maintain pairing to miR-NAs, suggesting that most mammalian mRNAs are conserved targets of miRNAs [3]. Since one miRNA can target many mRNAs, miRNAs play crucial roles in various cellular processes, including development, angiogenesis, cell cycle, and cellular migration [4]. Over the past decade, emerging evidences have demonstrated a central role for miRNAs in the occurrence and progression of human tumors [4, 5]. miR-NAs are abnormally expressed in human cancers and can act as either oncogenes or tumor suppressors [4-6]. Elucidating the function and mechanism of miRNAs will be particularly useful in improving cancer treatment.

Cervical cancer is the fourth leading cause of cancer mortality in women worldwide [7].

Previous studies have shown that miRNAs are aberrantly expressed in cervical cancer [8, 9], which affect response to therapy and ultimately outcome [10-12]. It has been recently shown that miR-7 inhibits the expression of epidermal growth factor receptor (EGFR) in some types of cancer, such as ovarian and gastric cancers [13, 14]. EGFR overexpression and activation are observed in solid tumors including cervical cancer [15], and EGFR tyrosine kinase has become an important therapeutic target for cancer therapy. Furthermore, miR-7 has been reported to act as an oncomiR in different cellular contexts in renal cell carcinoma [16]. A recent study reported that miR-7 suppressed cervical cancer cells proliferation and promoted cell apoptosis through inhibition of expression of X-linked inhibitor of apoptosis protein [17]. In this study, we showed that miR-7 inhibited cervical cancer cells metastasis and invasion by inhibiting the expression of focal adhesion kinase (FAK). These results further our understanding of the mechanisms underlying human cervical cancer.

Materials and methods

Tissue samples

Forth cervical cancer tissues and thirty normal cervical tissues were collected between 2012 and 2014 from Taixing Hospital, Jiangsu, China. All specimens were carefully reviewed by two independent pathologists to confirm the presence of cervical cancer. All patients signed an informed consent form, and the study was approved by the Institute Research Medical Ethics Committee of the Medical College of Yangzhou University.

Cell line culture

Human cervical cancer cell lines (Hela and C33A) and 293T cell line were purchased from the Chinese Peking Union Medical College Cell Bank (Beijing, China). All cell lines were maintained in DMEM and RPMI 1640 supplemented with 10% fetal bovine serum (FBS) (HyClone Victoria, Australia), 100 IU/mL penicillin, and 100 mg/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO₂.

Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)

Total RNA was isolated using Trizol reagent (Invitrogen, San Diego, CA, USA) according to the manufacturer's instructions. Reverse transcriptions was performed using the Takara PrimeScript[™] First Strand cDNA Synthesis kit (Takara Bio, Inc., Dalian, Japan) according to the manufacturer's instructions. gRT-PCR was performed using the All-in-One[™] miRNA gRT-PCR Detection Kit (GeneCopoeia, Rockville, MD, USA) on an Applied Biosystems 7500 RealTime PCR system (Applied Biosystems, White Plains, NY, USA). The U6 small RNA and GAPDH mRNA were used as internal controls for miR-7 and FAK, respectively. All the reactions were run in triplicate. Primers for miR-7 and U6 were 5'-AGTCGCTAGCCACAAACC AGGAAGGGGAA-3' and 5'-ATCGGAATTCAAATG-ATAAAGCCTGAAGTC-3', and 5'-CGCTTCGGCAG-CACATATAC-3' and 5'-TTCACGAATTTGCGTGTC-AT-3', respectively. Primers for FAK and GAPDH mRNAs were 5'-AGTAAAATCCAGCCAGCCCC-3' and 5'-GACATACTGCTGGGCCAGTT-3', and 5'-AAGGTGAAGGTCGGAGTCAAC-3', and 5'-GGGG-TCATTGATGGCAACAATA-3', respectively.

Transfection of cervical cancer cells

The miR-7-murine stem cell virus plasmid (MSCV) was chemically synthesized at the Department of Pathology, Medical College of Yangzhou University, and sequenced by Sangon Biotech (Shanghai) Co., Ltd. (Shanghai, China). Hela and C33A cells were transfected with 4-10 μ g miR-7-MSCV plasmid which at 37°C with 5% CO₂. MSCV empty vector was used as the negative control (NC).

Dual luciferase reporter assay

The full length 3'UTR of FAK (wild type, wt) was amplified by PCR from genomic DNA and cloned into the EcoRI and Xhal sites of pGL3-BS vector (Promega, Madison, WI, USA). The primer sequences used were as follows: forward, 5'-CTCTAGCCTTCCACCAGCA-G-3'; reverse, 5'-AACAAGAACTTTACTGGTAA-3'. The mutant construct of FAK 3' UTR was generated using a Quick Change mutagenesis kit (Stratagene, Heidelberg, Germany). Cotransfection of reporter vectors, and miR-7-MSCV or NCs was performed using Lipofectamine 2000 (Invitrogen, San Diego, CA, USA). After 48 h incubation, dual luciferase activity was measured using the Dual-Luciferase[®] reporter assay system (Promega) according to the manufacturer's protocol.

Migration and invasion assay

In vitro cell migration and invasion assays were performed by using transwell chambers. For the migration assays, 4×10^4 cells were added into the upper chamber of 8-µm transwells (BD Bioscience, Franklin Lakes, NJ, USA). For the invasion assays, 8×10^4 cells were added into the upper chamber of 8-µm transwells pre-coated with Matrigel (BD Bioscience, USA). In both assays, cells were plated in medium without serum, and medium containing 10% FBS in the lower chamber served as the chemoattractant. After 14 h incubation, the cells that did not migrate or invade through the pores were carefully removed. Filters were fixed in 90% alcohol followed by crystal violet staining. Five random fields were counted per chamber using an inverted microscope (Olympus, Tokyo, Japan). All experiments were performed in triplicate.



Western blot analysis

Cells were collected and lysed in ice-cold RIPA buffer (Beyotime, Jiangsu, China) according to the manufacturer's instructions. Protein concentration was quantified using an Enhanced BCA protein assay kit (Beyotime, Jiangsu, China). The proteins were separated by SDS-PAGE, and transferred onto PVDF membranes (Millipore, Bedford, MA, USA). After blocked with 5% nonfat milk for 1.5 h at room temperature, membranes were incubated with anti-FAK antibody (Cell Signaling Technologies, Boston, MA, USA) at 1:1000 dilution for overnight at 4°C, followed by incubation with horseradish peroxidase conjugated mouse and rabbit secondary antibody (Beyotime) for 2 h at room temperature. The signals were detected using a FluorChem FC2 Imaging System (Alpha Innotech, San Leandro, CA, USA).

Statistical analysis

Statistical analyses were performed using SPSS 16.0 software package (SPSS Inc.,



Figure 1. miR-7 is downregulated in cervical cancer and associated with tumor metastasis. A. The levels of miR-7 in cervical cancer tissues (n = 40) were significantly lower than those in normal cervical tissues (n = 30). B. The levels of miR-7 in non-metastatic cervical cancer tissues (n = 23) were lower than those in metastatic cervical cancer tissues (n = 17). C. The levels of miR-7 in two cervical cancer cell lines were lower than that in human cervical cells. The expression level of miR-7 was normalized to U6 small nuclear RNA. **P* < 0.05, ***P* < 0.001.

Chicago, IL, USA). All graphs were made using Microsoft Office Excel 2010 software (Microsoft Corporation, Redmond, WA, USA). Data from three independent experiments were expressed as mean \pm SD. Differences were assessed by the two-tailed Student's t test. The relationship between FAK and miR-7 expressions was tested with two-tailed Pearson's correlation. A *P* value < 0.05 was considered statistically significant.

Results

miR-7 is downregulated in cervical cancer tissues and cell lines

We first evaluated the endogenous expression of miR-7 in human cervical cancer and normal cervical tissues. As shown in **Figure 1A**, miR-7 was downregulated in cervical cancer tissues compared to corresponding adjacent normal cervical tissues (P < 0.05) (**Figure 1A**). Furthermore, the level of miR-7 in metastatic cervical cancer was significantly lower compared with that in cancer without metastasis (P



< 0.05) (**Figure 1B**). Similarly, we also found that the levels of miR-7 in two cervical cancer cell lines were more lower than that in normal cervical cells (P < 0.001) (**Figure 1C**).

Overexpression of miR-7 inhibits cervical cancer cell migration and invasion

Since miR-7 is downregulated in patients with metastatic cervical cancer, we next evaluated whether upregulation of miR-7 inhibits cell migration and invasion in cervical cancer. Hela and C33A cells, which possess low miR-7 levels, were transfected with miR-7-MSCV. The ectopic expression efficiency was confirmed by qRT-PCR (Figure 2). We found that overexpression of miR-7 in both Hela and C33A cells resulted in reduced migration and invasion rates (Figure 3). These results suggest that miR-7 may function as a tumor suppressor miRNA and contribute to inhibition of migration and invasion of cervical cancer cells.

miR-7 negatively regulates FAK gene expression

Previous studies have demonstrated that FAK is the target of miR-7 [18, 19]. To better elucidate the mechanisms underlying miR-7 function in cervical cancer cells, we further adopted an EGFR reporter system to confirm the direct regulation of FAK mRNA by miR-7. We constructed two vectors containing the wild-type and mutant FAK 3'UTR fragment, respectively. As shown in Figure 4, co-transfection of 293T cells with FAK-3'UTR/pGL3-BS (wt) and miR-7-MSCV caused a significant decrease in the luciferase activity compared with co-transfected FAK-3' UTR/pGL3 (mut) with miR-7-MSCV as negative control (P < 0.05). The levels of FAK mRNA and protein in both Hela and C33A cells with miR-7 overexpression were significantly (Figure 5A and 5B). This result indicated that miR-7 exerts inhibitory effects on FAK expression via interaction with FAK 3'UTR.



Figure 3. miR-7 inhibits cell migration and invasion. A. Transwell migration assays of Hela and C33A cells transfected with miR-7-MSCV and control vector. B. Transwell invasion assays of Hela and C33A cells transfected with miR-7-MSCV and control vector. *P < 0.05, **P < 0.001.



Figure 4. miR-7 inhibits FAK expression by directly targeting its 3'UTR. A. The potential binding sequences for miR-7 within the FAK 3'UTR of human (Hsa), chimpanzee (Ptr), rhesus (MmI), bushbaby (Oga), tree shrew (Tbe), and mouse (Mmu). Seed sequences are highlighted and underlined. B. The sequences of the predicted miR-7 binding sites (highlighted and underlined) within the human FAK 3'UTR, including wide-type full-length UTR and mutant UTR, are shown. C. Relative luciferase activity was analyzed upon transfection with reporter plasmids and miR-7-MSCV or control vector in 293T cells.

The mRNA level of FAK was further evaluated in cervical cancer and normal cervical tissues. As

shown in **Figure 5C**, there was a significant inverse correlation between FAK mRNA expres-



Figure 5. FAK is downregulated in Hela and C33A cells transfected with miR-7-MSCV.Relative expression of FAK mRNA by qPCR (top) and FAK protein expression by western blot (bottom) in Hela (A) and C33A cells (B) transfected with miR-7-MSCV and control vector. *P < 0.05, **P < 0.001. There were inverse correlations between miR-7 and FAK expression in 40 cervical cancer tissues (C) (r = 0.750; P < 0.05) and 17 metastatic cervical cancer tissues (D) (r = 0.820; P < 0.05) by detecting mRNA expression.

sion and miR-7 expression (r = -0.750, P < 0.05). Furthermore, a significant inverse correlation was also observed in metastatic cases (r = -0.820; P < 0.05).

Discussion

miRNAs specifically prevent protein production by binding to the 3'UTR of target mRNAs. This recruits RISC, which facilitates nucleolytic cleavage or inhibits translation of target mRNAs. By post-transcriptional regulation of protein production, a number of miRNAs can act as oncogenes or tumor suppressor genes. In the present study, we found that miR-7 was downregulated in cervical cancer tissues and cell lines. miR-17 suppressed the metastasis and invasion of cervical cancer cell by inhibiting FAK expression. These results indicate that miR-7 play an important role in the progression of cervical cancer.

Previous studies have shown that miR-7 is involved in some human diseases. As a direct regulator of a-synuclein, miR-7 has been proposed to play a role in Parkinson's disease [20]. Inhibition of miR-7 in pancreatic B cells induced mTOR signaling with subsequent stimulatory effects on cellular proliferation [21]. This suggests miR-7 may contribute to low B-cell renewal and could serve as a possible therapeutic target in diabetes mellitus. In addition, miR-7

directly targets and downregulates central oncogenic factors in cancer-associated signaling pathways including EGFR [13, 14], FAK [18, 19], Pak1 [22], and SETDB1 [23], clearly indicating a tumor-suppressive role of miR-7. In the present study, we found that miR-7 was downregulated in cervical cancer, especially metastatic tumors. In addition, there was an inverse correlation between miR-7 and FAK expression in cervical cancer. FAK is negatively regulated by miR-7, which is consistent with previous findings [18, 19]. miR-7 inhibits Hela and C33A cell migration and invasion through the FAK signaling. These results suggest that dysregulation of the FAK signaling pathway by miR-7 may be an important mechanism underlying metastasis and invasion in cervical. Further studies should examine the molecular mechanism by which miR-7 function as a tumor suppressor gene in the development and progression of cervical cancer.

FAK is an important adhesion kinase that contributes to extracellular matrix (ECM) integrin signaling, cell motility, proliferation, and survival. Increased FAK expression is observed in a variety of solid tumors and associated with metastatic disease and poor prognosis [24, 25]. FAK signaling regulates cancer growth and metastasis [26-28]. Increased FAK expression in precursor lesions and frankly invasive cervical cancer is an intriguing finding because an inverse relationship between p53 and FAK has been reported, which is consistent with p53 instability due to a HPV E6 viral protein as an essential etiologic factor [29]. FAK may function as an oncogene in the process of cervical cancer.

In conclusion, our study demonstrated that miR-7 suppressed cervical cancer metastasis and invasion through targeting FAK. miR-7 may be a potential therapeutic target for the treatment of metastatic cervical cancer.

Acknowledgements

This work was supported by the China National Science Foundation (Grant No. 81302041), Jiangsu Traditional Chinese Medicine Science and Technology Project Foundation for 2013 (Grant No. LZ13206), and the Jiangsu Higher Education Science Foundation (Grant No. 320007).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Jing Qian, Jiangsu Key Laboratory of Intergrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou University, Yangzhou 225001, Jiangshu, China. Tel: +86 514-87978867; Fax: +86 523-87633149; E-mail: jing234qian@163. com

References

- Fabian MR, Sonenberg N and Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79: 351-379.
- [2] Guo H, Ingolia NT, Weissman JS and Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
- [3] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
- [4] Farazi TA, Spitzer JI, Morozov P and Tuschl T. miRNAs in human cancer. J Pathol 2011; 223: 102-115.
- [5] Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H and Yu H. Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res 2014; 6: 391-401.
- [6] Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang X, Dai G and Huang J. Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer. Med Oncol 2014; 31: 283.
- [7] Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
- [8] Sharma G, Dua P and Agarwal SM. A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer. Curr Genomics 2014; 15: 310-323.
- [9] Villegas-Ruiz V, Juarez-Mendez S, Perez-Gonzalez OA, Arreola H, Paniagua-Garcia L, Parra-Melquiadez M, Peralta-Rodriguez R, Lopez-Romero R, Monroy-Garcia A, Mantilla-Morales A, Gomez-Gutierrez G, Roman-Bassaure E and Salcedo M. Heterogeneity of microRNAs expression in cervical cancer cells: over-expression of miR-196a. Int J Clin Exp Pathol 2014; 7: 1389-1401.
- [10] Wang N, Zhou Y, Zheng L and Li H. MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. Gynecol Oncol 2014; 134: 129-137.
- [11] Yuan W, Xiaoyun H, Haifeng Q, Jing L, Weixu H, Ruofan D, Jinjin Y and Zongji S. MicroRNA-218 enhances the radiosensitivity of human cervi-

cal cancer via promoting radiation induced apoptosis. Int J Med Sci 2014; 11: 691-696.

- [12] Zhang B, Chen J, Ren Z, Chen Y, Li J, Miao X, Song Y, Zhao T, Li Y, Shi Y, Ren D and Liu J. A specific miRNA signature promotes radioresistance of human cervical cancer cells. Cancer Cell Int 2013; 13: 118.
- [13] Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, Di W and Qiu L. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer. PLoS One 2014; 9: e96718.
- [14] Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu YP, Gui QJ, Zhang L and Li GQ. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep 2014; 31: 1715-1722.
- [15] Li Q, Tang Y, Cheng X, Ji J, Zhang J and Zhou X. EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. Int J Clin Exp Pathol 2014; 7: 733-741.
- [16] Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, Lai Y and Li X. Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol 2013; 44: 669-677.
- [17] Liu S, Zhang P, Chen Z, Liu M, Li X and Tang H. MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. FEBS Lett 2013; 587: 2247-2253.
- [18] Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobie PE and Zhu T. MicroR-NA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One 2012; 7: e41523.
- [19] Wu DG, Wang YY, Fan LG, Luo H, Han B, Sun LH, Wang XF, Zhang JX, Cao L, Wang XR, You YP and Liu N. MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. Chin Med J (Engl) 2011; 124: 2616-2621.
- [20] Junn E, Lee KW, Jeong BS, Chan TW, Im JY and Mouradian MM. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A 2009; 106: 13052-13057.

- [21] Wang Y, Liu J, Liu C, Naji A and Stoffers DA. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic beta-cells. Diabetes 2013; 62: 887-895.
- [22] Reddy SD, Ohshiro K, Rayala SK and Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 2008; 68: 8195-8200.
- [23] Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, Jiang L, Zhang Y and Dou J. MiR-7, Inhibited Indirectly by LincRNA HOTAIR, Directly Inhibits SETDB1 and Reverses the EMT of Breast Cancer Stem Cells by Downregulating the STAT3 Pathway. Stem Cells 2014; 32: 2858-2868.
- [24] Chen Y, Xia X, Wang S, Wu X, Zhang J, Zhou Y, Tan Y, He S, Qiang F, Li A, Roe OD and Zhou J. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients. J Gastroenterol 2013; 48: 1034-1044.
- [25] Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N and Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis 2013; 28: 9-18.
- [26] Zhan Q, Huang RF, Liang XH, Ge MX, Jiang JW, Lin H and Zhou XL. FRAS1 knockdown reduces A549 cells migration and invasion through downregulation of FAK signaling. Int J Clin Exp Med 2014; 7: 1692-1697.
- [27] Dai Z, Zhou SL, Zhou ZJ, Bai DS, Xu XY, Fu XT, Chen Q, Zhao YM, Zhu K, Yu L, Yang GH, Wang Z, Wu WZ, Zhou J and Fan J. Capn4 contributes to tumour growth and metastasis of hepatocellular carcinoma by activation of the FAK-Src signalling pathways. J Pathol 2014; 234: 316-328.
- [28] Luedde T. MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma. Hepatology 2010; 52: 1164-1166.
- [29] Golubovskaya VM and Cance WG. Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 2007; 263: 103-153.